Graphite Bio Announces Participation in H.C. Wainwright Gene Therapy and Gene Editing Virtual Conference
March 28 2022 - 8:00AM
Business Wire
Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage,
next-generation gene editing company focused on developing
therapies that harness targeted gene integration to treat or cure
serious diseases, announced today that Josh Lehrer, M.D., M.Phil.,
chief executive officer of Graphite Bio, and Matthew Porteus, M.D.,
Ph.D., one of the company’s academic founders, will be featured
speakers on the “CRISPR and Beyond: Advancing Gene Editing
Techniques” panel at the H.C. Wainwright Gene Therapy and Gene
Editing Virtual Conference on Wednesday, March 30, 2022, at 4 p.m.
ET.
The panel discussion will be webcast live from Graphite Bio’s
website at www.graphitebio.com in the Investors section. A replay
of the webcast will be archived and available following the
event.
About Graphite Bio
Graphite Bio is a clinical-stage, next-generation gene editing
company harnessing high efficiency targeted gene integration to
develop a new class of therapies to potentially cure a wide range
of serious and life-threatening diseases. Graphite Bio is
pioneering a precision gene editing approach that could enable a
variety of applications to transform human health through its
potential to achieve one of medicine’s most elusive goals: to
precisely “find & replace” any gene in the genome. Graphite
Bio’s platform allows it to precisely correct mutations, replace
entire disease-causing genes with normal genes or insert new genes
into predetermined, safe locations. The company was co-founded by
academic pioneers in the fields of gene editing and gene therapy,
including Maria Grazia Roncarolo, M.D., and Matthew Porteus, M.D.,
Ph.D.
Learn more about Graphite Bio by visiting www.graphitebio.com
and following the company on LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220328005177/en/
Company Contact: Stephanie Yao VP, Communications and
Investor Relations 443-739-1423 syao@graphitebio.com
Investors: Stephanie Ascher Stern IR, Inc. 212-362-1200
ir@graphitebio.com
Media: Sheryl Seapy Real Chemistry 949-903-4750
media@graphitebio.com
Graphite Bio (NASDAQ:GRPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Graphite Bio (NASDAQ:GRPH)
Historical Stock Chart
From Jul 2023 to Jul 2024